CeriBell, Inc. (NASDAQ:CBLL) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Brenda Bartman on May 16th, 2026

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $22.20.

Several brokerages recently commented on CBLL. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Canaccord Genuity Group dropped their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, BTIG Research restated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th.

Get Our Latest Stock Report on CeriBell

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $16.30 on Friday. The company’s fifty day moving average price is $19.11 and its 200 day moving average price is $18.88. CeriBell has a 12 month low of $10.85 and a 12 month high of $24.33. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 9.35. The firm has a market capitalization of $618.42 million, a P/E ratio of -10.00 and a beta of 0.99.

CeriBell (NASDAQ:CBLL – Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. As a group, sell-side analysts predict that CeriBell will post -1.68 earnings per share for the current fiscal year.

Insider Buying and Selling at CeriBell

In other CeriBell news, Director Josef Parvizi sold 16,714 shares of CeriBell stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $20.27, for a total value of $338,792.78. Following the transaction, the director directly owned 722,652 shares in the company, valued at approximately $14,648,156.04. The trade was a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Xingjuan Chao sold 39,000 shares of CeriBell stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.45, for a total transaction of $680,550.00. Following the completion of the transaction, the chief executive officer owned 711,164 shares in the company, valued at approximately $12,409,811.80. This represents a 5.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 175,119 shares of company stock valued at $3,310,772. Company insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

Several hedge funds and other institutional investors have recently made changes to their positions in CBLL. Bank of New York Mellon Corp boosted its holdings in shares of CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc purchased a new stake in shares of CeriBell in the fourth quarter valued at about $21,930,000. Royce & Associates LP purchased a new stake in shares of CeriBell in the fourth quarter valued at about $11,695,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of CeriBell in the fourth quarter valued at about $10,965,000. Finally, CenterBook Partners LP boosted its holdings in shares of CeriBell by 448.0% in the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after acquiring an additional 389,584 shares in the last quarter.

About CeriBell

(Get Free Report)

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

Analyst Recommendations for CeriBell (NASDAQ:CBLL)

Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.